According to the CTNeoBC pooled analysis of NAC clinical trials, among patients with TNBC, the strongest correlation was observed between pCR and long-term outcomes(EFS: HR 0.24, 95% CI 0.18-0.33; OS: 0.16, 0.11-0.25), particularly among patients with HR-negative/HER2-positive cancers. This evidence concerns the gene ERBB2 and cancer.